The board of directors of CombiGene AB (publ) (“CombiGene”) has, on the basis of an authorization from the Annual General Meeting, resolved on a directed share issue of 1,561,365 shares to Lipigon Pharmaceuticals AB (“Lipigon”) due to the license agreement previously concluded between CombiGene and Lipigon.
The share issue is carried out in order to pay the second interim payment to Lipigon under the license agreement. The second interim payment amounts to SEK 1,499,999.63 and is paid by a new issue of 1,561,365 shares. The number of shares has been determined on the basis of a subscription price corresponding to the volume weighted average price of CombiGene’s share during a period of fifteen (15) trading days ending the day before the board of director’s resolution on the issue of shares.
The interim payment follows CombiGene’s patent protection application for vectors developed within the lipodystrophy project CGT2, made on 24 August 2020. For further information on the patent application see press release “CombiGene applies for patent protection for vectors in the lipodystrophy project CGT2” from 25 August 2020. The share issue represents a dilution of approximately 0.88 percent of the share capital of CombiGene after the share issue. The new shares will be transferred to Lipigon as soon as the issue has been registered with the Swedish Companies Registration Office.